A Phase II Trial of Margetuximab in Combination With Tucatinib and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Capecitabine (Primary) ; Margetuximab (Primary) ; Tucatinib (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms MARGARET
Most Recent Events
- 06 Jul 2022 Status changed from not yet recruiting to withdrawn prior to enrolment on funder's decision.
- 10 Feb 2022 New trial record